Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Germain

Showing results (281-290 of 332) with videos related to

Pageof 34
Sort By:
Orphanet Journal of Rare Diseases|November 27, 2012
Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studiesDominique P Germain, Roberto Giugliani, Derralynn A Hughes, et al.
Orphanet Journal of Rare Diseases|December 6, 2019
Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs QuestionnaireEsther Noël, Bertrand Dussol, Didier Lacombe, et al.
Molecular Genetics and Metabolism|January 10, 2012
Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry RegistryWilliam R Wilcox, Gabor E Linthorst, Dominique P Germain, et al.
CNS Neuroscience & Therapeutics|June 15, 2016
Pain in Fabry Disease: Practical Recommendations for Diagnosis and TreatmentJuan M Politei, Didier Bouhassira, Dominique P Germain, et al.
Retina (Philadelphia, Pa.)|October 1, 2019
IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASEAndrea Sodi, Dominique P Germain, Daniela Bacherini, et al.
Molecular Genetics and Metabolism Reports|November 9, 2020
Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotypeRobert J Hopkin, Ulla Feldt-Rasmussen, Dominique P Germain, et al.
La Revue De Medecine Interne|January 8, 2011
[Enzyme replacement therapy of lysosomal storage diseases]D P Germain, C Boucly, R Y Carlier, et al.
Molecular Genetics and Metabolism|March 14, 2018
Fabry disease revisited: Management and treatment recommendations for adult patientsAlberto Ortiz, Dominique P Germain, Robert J Desnick, et al.
Molecular Genetics and Metabolism|November 21, 2007
Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry diseaseChristiane Auray-Blais, Denis Cyr, Aimé Ntwari, et al.
Molecular Genetics and Metabolism|August 12, 2011
The use of dried blood spot samples in the diagnosis of lysosomal storage disorders--current status and perspectivesArnold J Reuser, Frans W Verheijen, Deeksha Bali, et al.
Pageof 34

Showing results (281-290 of 332) with videos related to

Sort By:
Pageof 34
Orphanet Journal of Rare Diseases|November 27, 2012
Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studiesDominique P Germain, Roberto Giugliani, Derralynn A Hughes, et al.
Orphanet Journal of Rare Diseases|December 6, 2019
Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs QuestionnaireEsther Noël, Bertrand Dussol, Didier Lacombe, et al.
Molecular Genetics and Metabolism|January 10, 2012
Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry RegistryWilliam R Wilcox, Gabor E Linthorst, Dominique P Germain, et al.
CNS Neuroscience & Therapeutics|June 15, 2016
Pain in Fabry Disease: Practical Recommendations for Diagnosis and TreatmentJuan M Politei, Didier Bouhassira, Dominique P Germain, et al.
Retina (Philadelphia, Pa.)|October 1, 2019
IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASEAndrea Sodi, Dominique P Germain, Daniela Bacherini, et al.
Molecular Genetics and Metabolism Reports|November 9, 2020
Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotypeRobert J Hopkin, Ulla Feldt-Rasmussen, Dominique P Germain, et al.
La Revue De Medecine Interne|January 8, 2011
[Enzyme replacement therapy of lysosomal storage diseases]D P Germain, C Boucly, R Y Carlier, et al.
Molecular Genetics and Metabolism|March 14, 2018
Fabry disease revisited: Management and treatment recommendations for adult patientsAlberto Ortiz, Dominique P Germain, Robert J Desnick, et al.
Molecular Genetics and Metabolism|November 21, 2007
Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry diseaseChristiane Auray-Blais, Denis Cyr, Aimé Ntwari, et al.
Molecular Genetics and Metabolism|August 12, 2011
The use of dried blood spot samples in the diagnosis of lysosomal storage disorders--current status and perspectivesArnold J Reuser, Frans W Verheijen, Deeksha Bali, et al.
Pageof 34